Nasdaq 100 Stocks SEC Filings — July 16, 2026

Revenue surged 19% YoY to $2.89B, driven by 16% worldwide procedure growth (da Vinci +15%, Ion +36%), with GAAP net income up 24% YoY to $818M, signaling strong demand for robotic surgery

Q2 revenue of $12.6B grew 13% YoY (12% FX-neutral), with ads revenue on track to roughly double to ~$3B in 2026, indicating successful monetization of the ad-tier and a new growth engine

Repurchased 0.9M shares for $0.38B in Q2 2026, demonstrating confidence in intrinsic value and a shareholder-friendly capital allocation strategy

Engagement grew 2% in H1 2026 (vs 1.5% in 2025), showing accelerating user stickiness despite major sports events like the Winter Olympics and World Cup, a positive for retention

CEO Michael Intrator sold $8.15M in stock via a 10b5-1 plan across 15 transactions at ~$79.93, a large insider sale that may signal perceived overvaluation or personal diversification at a high-growth AI infrastructure company

CFO Andrew Dickinson sold $390K and Chief Comm Officer Johanna Mercier sold $390K of stock at ~$129.92 under 10b5-1 plans, a coordinated senior leadership sale that could indicate caution on near-term prospects

Three separate Form 4 filings show senior executives (CAO, President of Checkout, EVP Risk) had shares withheld for taxes, with the EVP Risk Officer's transaction totaling $184K, reflecting routine but notable insider activity at a stock price of $47.37 [NEUTRAL/BEARISH]

Narrowed 2026 revenue guidance to $51.0-$51.4B (13-14% growth) and reiterated 31.5% operating margin, providing clarity and a stable outlook despite Q2 margin decline from 34.1% to 33.4%

Non-GAAP gross profit margin guidance of 68.0%-69.0% reflects an estimated 1.0% revenue headwind from tariffs, a manageable but real cost pressure that could compress margins if tariffs expand

Operating margin declined from 34.1% in Q2 2025 to 33.4% in Q2 2026 (-70 bps YoY), and net income growth slowed to 9% YoY despite 13% revenue growth, signaling rising content costs and potential margin pressure ahead

CEO Michael Intrator sold $8.15M in stock across 15 transactions at an average price of ~$79.93, representing a significant liquidation that could signal insider concern about valuation or business momentum at a high-growth AI infrastructure firm

Both the CFO ($390K) and Chief Comm Officer ($390K) sold stock on the same day at $129.92 under 10b5-1 plans, a rare coordinated senior leadership sale that raises questions about upcoming catalysts or pipeline setbacks

Content amortization expected to grow ~10% for 2026, with slower growth in H2, but Q2 already showed margin compression, suggesting content investment may outpace revenue growth in the near term

2026 outlook includes an estimated 1.0% revenue impact from tariffs, with non-GAAP gross profit margin expected in a range of 68.0%-69.0%, creating uncertainty if trade policies escalate

Three senior executives (CAO, President of Checkout, EVP Risk) had shares withheld for taxes totaling ~$272K, with the EVP Risk Officer's transaction at $184K being the largest, indicating potential dilution or limited cash liquidity

UCAN Q2 revenue growth was only 10%, reflecting only a partial quarter impact from a recent price change, suggesting mature market saturation and reliance on international markets for growth

Share-based compensation expense rose to $213M in Q2 2026 from $200M in Q2 2025 (+6.5% YoY), diluting shareholders and reducing GAAP profitability

16% worldwide procedure growth (da Vinci +15%, Ion +36%) with revenue up 19% YoY to $2.89B, and GAAP net income up 24% YoY to $818M, indicating strong adoption of robotic surgery and potential for continued outperformance

Ads revenue on track to roughly double to ~$3B in 2026, providing a high-margin second revenue stream that could boost overall margins as it scales, with engagement accelerating to 2% in H1 2026

Q2 revenue surpassed $4.0B in EMEA and $1.5B in both LATAM and APAC, with UCAN growing only 10%, suggesting significant runway in international markets where penetration is lower

Repurchased 0.9M shares for $0.38B in Q2 2026, signaling management's confidence in the stock and providing a floor under the share price

Engagement grew 2% in H1 2026 vs 1.5% in 2025, despite competition from major sports events, indicating improved content strategy and user retention that could support pricing power

Ion procedure growth of 36% YoY significantly outpaces da Vinci's 15%, highlighting a high-growth segment within the company that could drive future revenue acceleration

With stock at $47.37 and executives exercising options and having shares withheld for taxes, the transactions may indicate that insiders see value at current levels, especially if the company executes on its turnaround strategy

Narrowed 2026 revenue forecast to $51.0-$51.4B (13-14% growth) provides increased visibility and reduces uncertainty, potentially attracting long-term investors seeking stable growth

6 of 8 filings involve insider transactions (sales or tax withholdings), with CoreWeave's CEO selling $8.15M and Gilead's CFO and CCO both selling $390K each, signaling a broad pattern of insider de-risking despite strong operational results

Both Netflix and Intuitive Surgical show strong revenue growth (13% and 19% YoY respectively) but face margin headwinds—Netflix from content costs and Intuitive from tariffs—suggesting that maintaining profitability while scaling is a key challenge

Intuitive Surgical is aggressively buying back shares ($0.38B in Q2), while Netflix is investing heavily in content (amortization up ~10%), reflecting different stages of maturity and capital priorities within the same index

Both Netflix and Intuitive Surgical are seeing stronger growth outside the US (Netflix's EMEA/APAC/LATAM, Intuitive's global procedure growth), highlighting the importance of international expansion for NASDAQ-100 companies

Intuitive Surgical's explicit 1.0% revenue impact from tariffs and 68.0%-69.0% gross margin guidance suggests that trade policy is becoming a material factor for healthcare technology companies, a theme that may broaden

Watch for Q3 revenue and margin trends, especially ads revenue growth and engagement metrics, to see if margin compression is temporary or structural. Next earnings expected in October 2026

Monitor trade policy announcements and Q3 2026 earnings for updates on tariff impact and gross margin trajectory, given the 1.0% revenue headwind guidance

Watch for additional insider sales or any public statements from management, as the $8.15M sale by the CEO could be followed by more selling or a secondary offering

Monitor for any FDA decisions or clinical trial readouts that could explain the coordinated CFO and CCO sales, as the $390K each sale may precede negative news

Track PayPal's stock at $47.37 and watch for any insider buying or company announcements, as the multiple tax-withholding filings could indicate a floor or further downside

Watch for any changes to 2026 content amortization guidance (~10% growth) and H2 spending patterns, as slower growth in H2 could signal a shift in strategy

Monitor whether the $0.38B buyback in Q2 accelerates in H2 2026, which would signal increased management confidence and provide support for the stock